Translational Development Acquisition and ProLogium amend their $3.9 billion merger agreement
Translational Development Acquisition and ProLogium signed an amendment to their merger agreement that sets ProLogium's equity value at $3.9 billion and establishes the number of shares used to determine the recapitalization factor. The amendment revises the share exchange, the post-closing board composition and voting structure, and moves the arbitration seat to Singapore. The transaction remains subject to closing conditions.
In 25 seconds
- The amendment sets ProLogium's equity value at $3.9 billion.
- It establishes the number of shares used to determine the recapitalization factor.
- The amendment revises the share exchange and post-closing corporate governance.
IASummary generated by artificial intelligence from a story by TradingView. It may contain errors: the original source prevails.




Comments
Be respectful. Comments reported by several people are hidden until a moderator reviews them.
You do not need an account to read, only to comment. Sign in with a code sent to your email or with your Google account. We only show the name you choose, never your email.